Biodesix, Inc. (NASDAQ:BDSX) Receives $32.50 Consensus PT from Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has earned a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $32.50.

BDSX has been the subject of several recent research reports. Canaccord Genuity Group set a $20.00 target price on shares of Biodesix and gave the stock a “buy” rating in a research report on Friday, September 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday. Finally, Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Biodesix Price Performance

BDSX opened at $6.82 on Monday. The company has a market capitalization of $54.29 million, a PE ratio of -1.23 and a beta of 0.62. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $31.20. The business has a 50-day moving average of $7.37 and a 200-day moving average of $7.34.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to analysts’ expectations of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Equities research analysts forecast that Biodesix will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Biodesix

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDSX. Birchview Capital LP raised its position in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company’s stock valued at $3,586,000 after purchasing an additional 154,937 shares during the period. XTX Topco Ltd raised its holdings in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the period. Oracle Investment Management Inc. acquired a new position in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new position in Biodesix during the 3rd quarter worth $113,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.